StockData
Johnson & Johnson logo

Johnson & Johnson

JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$270.56−2.64 (-0.97%)

Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%

Johnson & Johnson RISPERDAL CONSTA [reported separately through FY2022Q4] by Quarter

RISPERDAL CONSTA (risperidone) [reported separately through FY2022Q4] — U.S. sales ($M) ($M)

QuarterlyAnnual

Johnson & Johnson RISPERDAL CONSTA [reported separately through FY2022Q4]: $133M in Q4 2022, down 1,208.3% from a year earlier. That is the highest of the 25 quarters on record here. No newer figure appears in the documents we track.

Latest, Q4 2022
133
Period ended Jan 1, 2023
Change on a year earlier
-1,208.3%
-12 in Q4 2021
History
25 quarters
Since Q4 2016
Sources
18
Documents cited below

Where the Q4 2022 figure comes from

Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)

Source: Form 10-K (filed 2024-02-16) ↗

Reported in Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedRISPERDAL CONSTA (risperidone) [reported separately through FY2022Q4] — U.S. sales ($M) ($M)Year on yearSource
Q4 2022Jan 1, 2023133-1,208.3%Form 10-K (filed 2024-02-16) ↗
Q3 2022Oct 2, 202267-5.6%Form 10-Q (filed 2022-10-27) ↗
Q2 2022Jul 3, 202265-9.7%Form 10-Q (filed 2022-07-29) ↗
Q1 2022Apr 3, 202263-6.0%Form 10-Q (filed 2022-04-29) ↗
Q4 2021Jan 2, 2022-12-115.8%Form 10-K (filed 2024-02-16) ↗
Q3 2021Oct 3, 202171+1.4%Form 10-Q (filed 2022-10-27) ↗
Q2 2021Jul 4, 202172-2.7%Form 10-Q (filed 2022-07-29) ↗
Q1 2021Apr 4, 202167-11.8%Form 10-Q (filed 2022-04-29) ↗
Q4 2020Jan 3, 202176-1.3%Form 10-K (filed 2023-02-16) ↗
Q3 2020Sep 27, 202070-11.4%Form 10-Q (filed 2021-10-29) ↗
Q2 2020Jun 28, 202074-8.6%Form 10-Q (filed 2021-07-29) ↗
Q1 2020Mar 29, 202076-1.3%Form 10-Q (filed 2021-04-30) ↗
Q4 2019Dec 29, 2019770.0%Form 10-K (filed 2022-02-17) ↗
Q3 2019Sep 29, 201979+3.9%Form 10-Q (filed 2020-10-23) ↗
Q2 2019Jun 30, 201981+1.2%Form 10-Q (filed 2020-07-24) ↗
Q1 2019Mar 31, 201977-6.1%Form 10-Q (filed 2019-05-01) ↗

Breakdown

What makes up RISPERDAL CONSTA [reported separately through FY2022Q4]

Cite this data

StockData. (2026). Johnson & Johnson RISPERDAL CONSTA [reported separately through FY2022Q4] ($M), quarterly Q4 2016–Q4 2022 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-risperdal-consta-us

See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.